NCT05285358 2026-03-13
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
Phase 1 Recruiting
Clinical Trials
62 trialsNCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06109779 2026-03-04
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Phase 3 Active not recruiting
NCT06282575 2026-02-24
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT06048133 2026-01-23
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT06546969 2025-12-10
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
University of Maryland, Baltimore
Phase 1 Recruiting
NCT06440993 2025-12-01
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT05967182 2025-10-24
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT03656536 2025-08-24
FIGHT-302
Incyte Corporation
Phase 3 Terminated
NCT02784795 2025-08-21
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02375880 2025-08-03
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
Leap Therapeutics, Inc.
Phase 1 Completed
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT04521686 2025-06-27
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT07030140 2025-06-22
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT07025174 2025-06-17
SAIB
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT04003636 2025-04-23
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05342194 2025-04-23
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT04924062 2025-04-17
MK-3475-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06923475 2025-04-11
NEODISCO
Amsterdam UMC, location VUmc
Phase 2/3 Not yet recruiting
NCT02170090 2025-03-30
ACTICCA-1
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Active not recruiting
NCT05655949 2025-03-10
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06037980 2025-02-17
PURITY
Gruppo Oncologico del Nord-Ovest
Phase 2/3 Recruiting
NCT05532059 2025-02-10
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06721286 2024-12-06
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT02512692 2024-11-18
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
Medical University of South Carolina
Phase NA Terminated
NCT06341764 2024-11-07
Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
National Cancer Institute, Naples
Phase 2 Recruiting
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT06375915 2024-05-24
PM-CARE
IRCCS San Raffaele
Phase 2 Recruiting
NCT03773302 2024-05-08
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT04088188 2024-05-06
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Academic and Community Cancer Research United
Phase 1 Terminated
NCT02452970 2024-04-24
EPIC
EpicentRx, Inc.
Phase 2 Terminated
NCT01825603 2023-12-28
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
University of Nebraska
Phase 1 Completed
NCT05514912 2023-12-26
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Emory University
Phase 2 Withdrawn
NCT03684811 2023-11-18
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed
NCT04066491 2023-11-14
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
Phase 2/3 Terminated
NCT03473574 2023-06-15
IMMUCHEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT02351765 2023-05-17
ABC-08
The Christie NHS Foundation Trust
Phase 1 Completed
NCT05672537 2023-01-05
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03102320 2022-06-30
ARCS-Multi
Bayer
Phase 1 Completed
NCT04546828 2022-06-15
A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
Samsung Medical Center
Phase 2 Withdrawn
NCT04480190 2022-04-20
Neoadjuvant Therapy in Biliary Adenocarcinoma
University of Cincinnati
Phase 1 Withdrawn
NCT03086993 2022-03-24
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Delcath Systems Inc.
Phase 2/3 Unknown
NCT02392637 2022-02-02
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02128282 2021-10-22
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Senhwa Biosciences, Inc.
Phase 1/2 Completed
NCT02631590 2021-08-04
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed